July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
No survival advantage for first-line liposomal irinotecan patients with pancreatic adenocarcinoma
Jun 9, 2024, 14:57

No survival advantage for first-line liposomal irinotecan patients with pancreatic adenocarcinoma

Mark Lewis shared on X:

“Important abstract (GIANT, or EA2186) from ASCO24 which does NOT show a survival advantage for first-line liposomal irinotecan (vs. gemcitabine/Abraxane) in elderly (70 or older, median = 77) patients with pancreatic adenocarcinoma.”

Read further
Source: Mark Lewis/X

Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.